TBPH
Theravance Biopharma Inc
NASDAQ: TBPH · HEALTHCARE · BIOTECHNOLOGY
$16.52
-0.49% today
Updated 2026-06-05
Market cap
$908.88M
P/E ratio
7.91
P/S ratio
8.28x
EPS (TTM)
$2.23
Dividend yield
—
52W range
$11 – $21
Volume
0.4M
WallStSmart proprietary scores
47
out of 100
Grade: C
Sell
Investment rating
7.3
Growth
B+7.0
Quality
B+6.5
Profitability
B8.3
Valuation
A5/9
Piotroski F-Score
Moderate
0.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →205 stocks currently score above 75
Price targets
Analyst target
$17.40
+5.33%
12-Month target
$15.29
-7.45%
Intrinsic (DCF)
$59.74
Margin of safety
+67.34%
0 Strong Buy3 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 104.30% — above average
+ ROE 39.42% — strong efficiency
+ Free cash flow $73.28M — positive
+ Revenue growth 15.00% QoQ
+ 67.34% below intrinsic value
Risks
- Altman Z 0.52 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $51.35M | $57.42M | $64.38M | $107.46M | $109.78M |
| Net income | $872.13M | $-55.19M | $-56.42M | $105.89M | $-4.93M |
| EPS | — | — | — | — | $2.23 |
| Free cash flow | $-187.56M | $-29.48M | $-11.87M | $238.50M | $73.28M |
| Profit margin | 1,698.54% | -96.11% | -87.63% | 98.54% | 104.30% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-20 | WINNINGHAM, RICK E | Sale | 20,038 | $16.55 |
| 2026-05-20 | SAWAF, AZIZ | Sale | 8,670 | $16.55 |
| 2026-05-20 | MILLER, AINE | Sale | 6,827 | $16.55 |
Peer comparison
Smart narrative
Theravance Biopharma Inc trades at $16.52. representing a P/E of 7.91x trailing earnings. Our Smart Value Score of 47/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 0.52, it sits in the distress. TTM revenue stands at $109.78M. with profit margins at 104.30%. Our DCF model estimates intrinsic value at $59.74.
Frequently asked questions
What is Theravance Biopharma Inc's stock price?
Theravance Biopharma Inc (TBPH) trades at $16.52, on a P/E of 7.9x and a P/S of 8.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Theravance Biopharma Inc overvalued?
Theravance Biopharma Inc carries a Smart Value Score of 47/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $59.74 versus the $16.52 price, a 67.3% margin of safety on a cash flow basis.
What is the price target of Theravance Biopharma Inc (TBPH)?
The 12-month analyst consensus target is $17.40, about 5.3% above the current $16.52. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of TBPH by 2030?
Our research-backed model puts the 2030 base case at $21.22, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Theravance Biopharma Inc (TBPH)?
Our DCF model estimates intrinsic value at $59.74, a +67.3% margin of safety versus today's $16.52. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Theravance Biopharma Inc's revenue?
Theravance Biopharma Inc's trailing twelve-month revenue is $109.78M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Theravance Biopharma Inc's Altman Z-Score is 0.52, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio8.28x
ROE39.42%
Beta0.18
50D MA$16.57
200D MA$16.72
Shares out0.05B
Float0.02B
Short ratio—
Avg volume0.4M
Performance
1 week+2.35%
1 month+4.37%
3 months+12.53%
YTD-9.30%
1 year—
3 years—
5 years—